Skip to main content
. 2020 May 12;10:7849. doi: 10.1038/s41598-020-63900-0

Figure 5.

Figure 5

VEGF-A but not GW0742 promotes HUVEC proliferation which requires an intact FAO pathway. (a) VEGF-A (25 ng/ml) but not GW0742 (100 nM) significantly increased HUVEC proliferation (24 h), as assessed by BrdU incorporation. Data represent mean (±S.E.M) percentage of BrdU+ cells from n = 3; *p < 0.05 vs. untreated control as determined by one-way repeated measures ANOVA followed by Tukey’s post-comparison test. (b) Representative images showing BrdU incorporation following control, VEGF-A (25 ng/ml) or GW0742 (100 nM) treatment for 24 h. (c) Representative Immunofluorescence images showing a significant reduction in CPT1A expression 48 h following transfection with CPT1A-targeting siRNA sequences (10 nM). (d) VEGF-A-induced (25 ng/ml; 24 h) proliferation (BrdU incorporation) was significantly reduced in CPT1A-silenced HUVEC. Data represent means (±S.E.M) of n = 3. **p < 0.01 as determined by two-way ANOVA followed by Bonferroni’s post-comparison test. (e) PPARβ/δ mRNA expression is significantly reduced in CPT1A-silenced cells 48 h post-transfection (n = 3). Data represent means (±S.E.M); *p < 0.05 vs. non-coding transfection control as determined by one-way ANOVA followed by Bonferroni’s post-comparison test.